The Journal of the Association of Physicians of India · 2021
Efficacy and Safety of Bioresorbable Vascular Scaffold (BVS) - Absorb in Acute Myocardial Infarction - A 45 Month Follow Up Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumar Viveka, Kumar Vivek, Yadav Mitendra Singh, Dhir Sangeeta, Nayak Pradipta
Аннотация
AIM: Bioresorbable vascular scaffolds (BVS) over the years have emerged as a new treatment option in coronary revascularization. There is a limited data on the use of these novel devices in patients with acute myocardial infarction (AMI). The purpose of this study was to evaluate the safety feasibility and efficacy of BVS implantation in patients with AMI.
METHODS AND RESULTS: 61 patients diagnosed for AMI underwent Absorb BVS device implantation. The mean age of the patients were 56.6 years with 86.89 % males. 34 patients has history of hypertension (HTN, 55.7%), 3 patients had history of myocardial infarction (MI,4.91 % ), 7 patients were diagnosed with unstable angina ( UA,11%), 34 patients had anterior wall ST elevation myocardial infarction ( AWSTEMI,55.73%),13 with ST segment elevation myocardial infarction ( STEMI,21.31%), with Killips class 2 (39.34%), 6 patients had Non ST segment Elevation Myocardial Infarction (NSTEMI, 9.83%). Procedural success was achieved in 93% patients with thrombolysis in myocardial infarction flow (TIMI) 3. During the follow up period of minimum 44±16 months no peri-procedural MACE were reported. Incidence of TLF (22.95%),definite probable ScT (11.47%) and TLR was 8 %. Average duration of DAPT was 17.57 months and 8 days. Cardiac death occurred in 4 patients (6.5%) after discharge from the hospital.
CONCLUSIONS: The study results suggest that BVS implantation is feasible and safe in AMI. Specific device implantation technique is critical step towards success of BVS devices.
METHODS AND RESULTS: 61 patients diagnosed for AMI underwent Absorb BVS device implantation. The mean age of the patients were 56.6 years with 86.89 % males. 34 patients has history of hypertension (HTN, 55.7%), 3 patients had history of myocardial infarction (MI,4.91 % ), 7 patients were diagnosed with unstable angina ( UA,11%), 34 patients had anterior wall ST elevation myocardial infarction ( AWSTEMI,55.73%),13 with ST segment elevation myocardial infarction ( STEMI,21.31%), with Killips class 2 (39.34%), 6 patients had Non ST segment Elevation Myocardial Infarction (NSTEMI, 9.83%). Procedural success was achieved in 93% patients with thrombolysis in myocardial infarction flow (TIMI) 3. During the follow up period of minimum 44±16 months no peri-procedural MACE were reported. Incidence of TLF (22.95%),definite probable ScT (11.47%) and TLR was 8 %. Average duration of DAPT was 17.57 months and 8 days. Cardiac death occurred in 4 patients (6.5%) after discharge from the hospital.
CONCLUSIONS: The study results suggest that BVS implantation is feasible and safe in AMI. Specific device implantation technique is critical step towards success of BVS devices.